AN ANALYSIS OF ANTIMICROBIAL AND ANTIDIABETIC FIXED DOSE COMBINATIONS BANNED IN INDIA
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i6.50741Keywords:
CDSCO, banned drugs, rational pharmacotherapy, DTAB subcommitteeAbstract
Objective: National regulatory authority reviewed various fixed-dose combinations (FDCs) in view of doubtful rationality status and subsequently 349 FDCs were banned in 2018. This study was conducted to analyze the antimicrobial and antidiabetic FDCs banned by the Central Drugs Standard Control Organization in India.
Methods: Data were collected from the report of drugs technical advisory board subcommittee. Banned antimicrobial and antidiabetic FDCs were assessed for the following parameters – number of active pharmacological ingredients, routes of administration and dosage forms, indications for marketing, reasons for banning, and pharmacological group of FDCs.
Results: Seventy antimicrobial and 25 antidiabetic FDCs were analyzed. These FDCs contained 2–7 drugs, available mostly as tablets (51.42%, 100%) in antimicrobial and antidiabetic groups, respectively. Antimicrobial FDCs were marketed most for respiratory tract infections and infection and inflammatory conditions of the skin (17, 24.28% each) while antidiabetic FDCs were marketed for Type 2 diabetes mellitus (14, 56%). The reasons for ban were pharmacodynamic (68.57%, 16%) and pharmacokinetic (20%, 40%) mismatches, lack of evidence of efficacy (7.14%, 36%), and safety concerns (4.28%, 8%) in antimicrobial and antidiabetic groups, respectively. In antimicrobial FDCs, the most common combination was that of an antibacterial with other miscellaneous drugs (like zinc, Vitamin E, serratiopeptidase, etc.) (19, 27.14%) whereas antidiabetic FDCs most commonly had biguanide with thiazolidinedione and sulfonylurea (7, 28%).
Conclusion: There is a need for scrutiny of other FDCs in larger interests of patient care and prescribers should be made aware about recently banned FDCs to promote rational pharmacotherapy.
Downloads
References
Thangaraju P, Varthya SB, Venkatesan S. Fixed-dose combinations: An essential for rational preparation. Indian J Pharmacol. 2021; 53(2):170-2.
System of Preliminary Scrutiny by CDSCO at the Time of Receipt of Application for Approval of Fixed Dose Combinations (FDCs). Available from: https://cdsco.gov.in/opencms/opencms/system/ modules/cdsco.web/elements/download_file_division.jsp?num_ id=mzi1mQ [Last accessed on 2023 Aug 19].
Tripathi KD. Aspects of pharmacotherapy, clinical pharmacology and drug development. In: Tripathi M, editor. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2019. p. 72.
Gupta YK, Ramachandran SS. Fixed dose drug combinations: Issues and challenges in India. Indian J Pharmacol. 2016;48(4):347-9.
Report of the DTAB Subcommittee. Available from: https://cdsco.gov. in/opencms/export/sites/cdsco_web/pdf-documents/committee/dtab_ sub_report.pdf [Last accessed on 2023 Aug 19].
Antimicrobial Resistance. World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance [Last accessed on 2023 Aug 19].
Diabetes. World Health Organization. Available from: https://www.who. int/health-topics/diabetes#tab=tab_1 [Last accessed on 2023 Aug 19].
Yosmar R, Shepany E, Fitria N. A comprehensive analysis of antidiabetic drug interactions in geriatric non-insulin dependent diabetes mellitus patients. Int J Appl Pharm. 2024;16(1):62-5.
Shah S, Patel J, Desai M, Dikshit RK. Critical analysis of antimicrobial and respiratory fixed dose combinations available in Indian market. Int J Med Public Health. 2015;5(2):161-4.
Sauriasari R, Apriyanti YF, Pramono D. Assessment of antibiotic prescription in patients with non-pneumonia acute respiratory tract infection. Int J Appl Pharm. 2018;10(1):66-9.
Rayasam SP, Dudhgaonkar SS, Dakhale GN, Hire RC, Deshmukh PS, Gaikwad NN. The irrational fixed dose combinations in the Indian drug market: An evaluation of prescribing pattern using WHO guidelines. Int J Basic Clin Pharmacol. 2013;2(4):452-7.
Dalal K, Ganguly B, Gor A. Assessment of rationality of fixed dose combinations approved in CDSCO list. J Clin Diagn Res. 2016;10(4):5-8.
Satoskar RS, Rege NN, Tripathi RK, Kamat SK, editors. Enzymes in therapy. In: Pharmacology and Pharmacotherapeutics. 26th ed. Mumbai: Elsevier; 2021. p. 979-81.
Tripathi KD. Insulin, oral antidiabetic drugs and glucagon. In: Tripathi M, editor. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2019. p. 280-305.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care. 2023 Jan;46(Suppl_1):S140-57.
Powers AC, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Knollmann BC, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw Hill; 2023. p. 1034-42.
Drug Interaction Checker. Drug Interactions Checker - Medscape Drug Reference Database. Available from: https://reference.medscape.com/ drug-interactionchecker [Last accessed on 2023 Aug 20].
Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Dr. Jitendra Hotwani, Dr. Ankita Rao
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
